Hydroxychloroquine, COVID-19 and diabetes. Why it is a different story

Anca Pantea Stoian, Doina Catrinoiu, Manfredi Rizzo, Antonio Ceriello

Research output: Contribution to journalComment/debatepeer-review


Hydroxychloroquine has been proposed for the cure of the COVID-19 due to its anti-inflammatory and anti-viral action. People with diabetes are more prone to severe outcome if affected by COVID-19 and the use of Hydroxychloroquine might have some benefit in this setting. However, the use of Hydroxychloroquine in diabetes deserves particular attention for its documented hypoglycemic action.

Original languageEnglish
Article numbere3379
JournalDiabetes/Metabolism Research and Reviews
Issue number2
Publication statusPublished - Feb 2021

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'Hydroxychloroquine, COVID-19 and diabetes. Why it is a different story'. Together they form a unique fingerprint.

Cite this